Type II Diabetes Mellitus

Type II Diabetes Mellitus
Objectives

  1. Anatomy and Physiology

    • Identify relevant anatomy and physiology related to type 2 diabetes mellitus.

  2. Epidemiology, Etiology, Pathophysiology

    • Differentiate aspects including epidemiology, etiology, pathophysiology, clinical presentation, diagnostic evaluation, differential diagnosis, and management.

  3. Diagnosis

    • Distinguish type 2 diabetes mellitus from differential diagnoses through history, physical examination findings, and diagnostic laboratory studies.

  4. Diagnostic Studies

    • Analyze the diagnostic laboratory studies involved in the diagnosis of type 2 diabetes mellitus.

  5. Specialist Referrals & Patient Education

    • Choose appropriate specialist referrals, prevention, health maintenance strategies, and patient education concerning type 2 diabetes mellitus.

Epidemiology

Prevalence of Diabetes

  • Total Cases: Approximately 38.4 million people (11.6% of the US population) are diagnosed with diabetes mellitus.

    • Type 2 Diabetes: This form of diabetes represents about 90-95% of all diabetes cases, highlighting its predominance in the diabetic population.

  • Diagnosed Cases: Of those, 29.1 million are diagnosed, including 28.8 million adults.

  • Undiagnosed Cases: About 11 million individuals remain undiagnosed, which stresses the importance of screening and awareness.

Prevalence of Prediabetes

  • Total Prediabetes Cases: There are around 115.2 million individuals aged over 18 years classified with prediabetes.

    • Aged ≥ 65 years: Specifically affecting 31.3 million older adults, making this age group particularly vulnerable.

Demographics

  • Type 2 diabetes is most frequently diagnosed in adults but is alarmingly becoming more prevalent among younger populations, including adolescents and even children.

  • It is a leading cause of complications such as blindness, renal failure, and serves as a significant contributor to mortality from cerebrovascular accidents (strokes) and cardiac events.

Anatomy, Physiology, and Pathophysiology
Physiology of Diabetes

Fuel Requirements and Insulin Regulation

  • Human cells primarily rely on glucose as a crucial source of energy, which is stored as glycogen primarily in the liver and muscles.

  • Hormonal Regulation: The regulation of glucose in the bloodstream relies heavily on the hormonal interplay between insulin and glucagon secreted by the pancreas.

    • Insulin: Released in response to elevated blood glucose levels, its primary roles include lowering glucose levels and promoting its storage in the form of glycogen and fat.

    • Glucagon: Released when blood glucose levels dip, it serves to raise glucose levels by signaling the liver to release stored glycogen.

Basal Insulin and Amylin Functions

  • Basal Insulin: This hormone is continuously produced in a low but steady manner.

    • When insulin levels are low, it triggers the liver to release glucose into the bloodstream, thereby increasing blood glucose levels.

  • Amylin: Secreted concurrently with insulin, this hormone contributes to post-meal satiety, slows down gastric emptying after meals, and inhibits glucagon release. This function helps maintain stable blood glucose levels following food intake.

Fasting State Physiology

  • During Fasting: Insufficient food intake leads to decreased blood glucose levels, which triggers glucagon release and reduces insulin secretion, ensuring that glucose is available for use by the brain and other essential tissues.

    • Processes Involved:

      • Glycogenolysis: The process by which glycogen is broken down into glucose.

      • Gluconeogenesis: The liver synthesizes glucose from precursors like lactate, amino acids, and glycerol, which is particularly crucial during prolonged fasting.

Prandial State Physiology

  • During Prandial and Postprandial States:

    • After meals, blood glucose levels rise, prompting the pancreas's beta cells to release insulin and amylin.

    • Incretins, such as GLP-1 and GIP, are released in response to food intake to further enhance insulin secretion and suppress glucagon, refining glucose regulation following meals.

Implications in Type 2 Diabetes Mellitus

  • In Type 2 diabetes, there exists an impairment in the insulin response along with inadequate suppression of glucagon, which leads to consistently elevated blood glucose levels.

    • Postprandial hyperglycemia occurs as glucose is not effectively utilized for energy during and after meals.

  • The enzyme Dipeptidyl Peptidase-4 (DPP-4), which inactivates incretins, plays a notable role in exacerbating glucose regulation issues, as lower incretin levels can lead to suboptimal insulin secretion and glucagon suppression.

Definition of Diabetes

  • Diabetes: A metabolic disorder characterized by elevated blood glucose levels due to either:

    • Insufficient insulin production from pancreatic beta cells, or

    • Inadequate cellular response to insulin (insulin resistance), which is often seen in obesity and metabolic syndrome.

  • The pathophysiology encompasses:

    • An increase in insulin production leading to conditions like hyperinsulinemia,

    • Impairments in insulin signaling pathways at the cellular level, and

    • Increased inappropriate secretion of glucagon, which notably contributes to hyperglycemia.

Monogenic Diabetes
Overview

  • Monogenic diabetes is the result of a mutation within a single gene, setting it apart from the polygenic causes of Type 1 and Type 2 diabetes. It is not associated with autoimmune responses or the development of insulin resistance, making it a unique subset of diabetes.

  • Types:

    1. Maturity-Onset Diabetes of the Young (MODY)

    2. Neonatal diabetes (rare, diagnosed in the first 6 months of life).

  • Characteristics: Typically characterized by hyperglycemia with impaired insulin secretion triggered by glucose presence, often manifesting before age 25, and commonly observed in individuals with a strong family history of diabetes but lacking acanthosis nigricans, which is often seen in Type 2 diabetes.

Latent Autoimmune Diabetes in Adults (LADA)
Description

  • LADA is a slowly progressing form of autoimmune diabetes that frequently gets misdiagnosed as Type 2 diabetes mellitus due to its onset in adulthood.

    • Diagnostic Clues:

      • Adult-onset diabetes,

      • Positive autoantibody presence in the blood, indicating an autoimmune reaction,

      • Preservation of insulin secretion for a longer duration in comparison to typical Type 1 diabetes.

  • Its clinical presentation may resemble Type 1.5 diabetes, noted by traits such as a lower body mass index (BMI) and an earlier age of diagnosis.

Symptoms of Type 2 Diabetes Mellitus

  • Common symptoms include:

    • Increased thirst (polydipsia),

    • Unexplained weight loss,

    • Increased hunger (polyphagia),

    • Fatigue,

    • Slow healing of wounds,

    • Numbness in extremities (hands and feet),

    • Blurred vision,

    • Frequent urination (polyuria),

    • Dry skin.

Clinical Presentation and Monitoring
Physical Examination Findings

  • A comprehensive physical examination may reveal:

    • Acanthosis nigricans (dark, velvety skin changes),

    • Xanthelasma (fatty deposits around the eyelids),

    • Signs of neuropathy, whether peripheral (numbness or pain) or autonomic (digestive issues).

  • Regular monitoring should include:

    • Psychosocial Assessment: Utilizing tools like the PHQ-9 to evaluate depression, which is common in diabetics.

    • Comprehensive foot examinations to prevent diabetic ulcers.

    • Routine blood pressure assessments and laboratory testing to evaluate glycemic status, including HbA1c measurements.

Diagnostic Evaluation
Diagnostic Criteria for Type II Diabetes Mellitus

  • Confirmatory tests to establish diagnosis must indicate one or more of the following:

    1. Fasting Plasma Glucose (FPG) ≥ 126 mg/dL,

    2. Random Plasma Glucose ≥ 200 mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis,

    3. 2-hour postprandial glucose (PPG) ≥ 200 mg/dL during an oral glucose tolerance test (OGTT),

    4. Hemoglobin A1c (HbA1c) ≥ 6.5%.

Other Laboratory Evaluations

  • Follow-up Assessments: Regular monitoring of glycemic status should occur at least twice yearly and should incorporate additional evaluations such as:

    • Comprehensive lipid panels to assess cardiovascular risk,

    • Liver function tests to monitor potential hepatic complications,

    • Urine albumin/creatinine ratio to evaluate kidney function,

    • Serum electrolytes and renal function tests to ensure systemic health.

Differential Diagnosis
Persistent Hyperglycemia Causes

  • Main differential diagnoses to consider:

    • Type 1 Diabetes Mellitus, characterized by autoimmune destruction of pancreatic insulin-producing cells.

    • Diseases of the exocrine pancreas, which can lead to insulin deficiency.

    • Drug-induced diabetes, stemming from medications such as glucocorticoids or certain antipsychotics.

    • Other metabolic disorders, including conditions that affect carbohydrate metabolism.

Management
Goals of Management

  • The primary objectives are to prevent disease progression and minimize risks of complications through effective management of:

    • Blood glucose levels,

    • Lipid profiles,

    • Blood pressure measurements.

American Diabetes Association (ADA) Treatment Recommendations

  1. First Line: Lifestyle modification (diet and exercise) combined with Metformin, which remains the cornerstone of diabetes management, with the possibility for adjunct treatment.

    • Insulin therapy may be warranted if A1C levels are ≥10% or if glucose levels exceed 300 mg/dL at diagnosis.

  2. Adjunctive Medications: The incorporation of newer medications like SGLT2 inhibitors and GLP-1 receptor agonists is recommended due to their proven cardiovascular and renal benefits.

  3. Weight Management: It is strongly encouraged as a complementary strategy alongside lifestyle modifications to achieve and maintain optimal glycemic control.